Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Current assets
Cash and cash equivalents	$ 110,890	$ 136,377
Restricted cash	110	110
Prepaid expenses	4,031	2,488
Research and development tax rebate receivable	743	1,072
Other current assets	2,423	1,193
Total current assets	118,197	141,240
Investment in equity securities	4,700	0
Other assets	635	22
Total Assets	123,532	141,262
Current liabilities
Accounts payable	2,965	1,717
Accrued expenses	1,059	204
Payroll liabilities	1,525	1,184
Other current liabilities	19	21
Total current liabilities	5,568	3,126
Total Liabilities	5,568	3,126
Commitments and contingencies (Note 14)
Stockholders' equity
Series B convertible preferred stock - $0.001 par value; 10,000 shares authorized; 1 shares issued and outstanding as of December 31, 2022 and December 31, 2021	0	0
Common stock - $0.18 par value; 175,000 shares authorized; 126,624 shares issued and outstanding as of December 31, 2022 and December 31, 2021	22,792	22,792
Additional paid-in capital - common stock	250,784	243,996
Accumulated deficit	(156,194)	(129,234)
Total Stockholders' Equity	117,964	138,136
Total Liabilities and Stockholders' Equity	123,532	141,262
Series B Preferred Stock [Member]
Stockholders' equity
Additional paid-in capital - Series B convertible preferred stock	$ 582	$ 582